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ochester, Minnesota
ontrast-induced nephropathy (CIN) is most commonly
efined as a 25% increase in serum creatinine concentration
rom the baseline value, or an absolute increase of at least
.5 mg/dl, that appears within 48 h after the administration
f radiographic contrast media in the absence of an alter-
ative cause (1). Contrast-induced nephropathy is the third
ost common cause of new acute renal failure in hospital-
zed patients (2). The incidence of CIN in the general
opulation has been reported to be 2% to 5%. However, the
ncidence may be as high as 25% in patients with pre-
xisting renal impairment or certain risk factors, such as
iabetes, congestive heart failure, advanced age, and con-
urrent administration of nephrotoxic drugs (3). Despite the
See page 1040
act that CIN most commonly manifests as a nonoliguric
nd asymptomatic transient decline in renal function, cohort
tudies have shown that it is associated with significant
orbidity and mortality rates independent of other risk
actors. Specifically, Levy et al. (4) reported in a study of
ore than 16,000 patients undergoing contrast-enhanced
xaminations that in patients who developed CIN, there
as a significantly higher mortality rate than in the patient
roup from the same population matched for age and
aseline creatinine levels who underwent similar contrast-
nhanced procedures but did not develop CIN (34% vs.
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himeric natriuretic peptides.%). Thus, CIN was found to result in excessive mortality
ates, independent of other risk factors.
Although the exact underlying mechanisms of CIN have
et to be fully elucidated, it is most likely multifactorial
ecause of increased adenosine, endothelin, and free-radical–
nduced vasoconstriction with decreased local prostaglandin
nd nitric oxide (NO)-mediated vasodilation resulting in renal
edulla ischemia (5). Contrast agents also have direct toxic
ffects on renal tubular cells, resulting in vacuolization, altered
itochondrial function, and apoptosis (6).
As with all medical conditions, the best treatment for
IN is to prevent it. General measures to minimize the
ncidence include using the minimal effective dose, elimi-
ating potentially nephrotoxic drugs at least 24 h before the
tudy, and adequate hydration. Several drug interventions,
ncluding the use of N-acetylcysteine, theophylline,
enoldopam, and other agents have been investigated as
reventive strategies in CIN; however, the results have been
eterogeneous and are difficult to compare across the
ifferent treatment strategies. In a recent meta-analysis by
elly et al. (7) that included 33 CIN prevention trials
nvolving 3,622 patients, the investigators reported that
-acetylcysteine is more renoprotective than hydration
lone and theophylline may also reduce risk for contrast-
nduced nephropathy, although the detected association was
ot significant. The remaining agents did not significantly
ffect risk. Importantly, the investigators pointed out that
he available studies used in the meta-analysis examined
aboratory end points (such as an increase in serum creati-
ine levels) rather than clinical end points (such as dialysis
r death).
In this issue of the Journal, Morikawa et al. (8) reported
single-center controlled, randomized trial designed to
xamine the protective effects of atrial natriuretic peptide
ANP) on CIN after coronary angiography. They random-
zed 254 consecutive patients with serum creatinine concen-
rations of 1.3 mg/dl, where patients received either ANP
r lactated Ringer solution alone initiated 4 to 6 h before
ngiography and continued for 48 h. The investigators
eported that the prevalence of CIN, defined as a 25%
ncrease in creatinine or an increase in creatinine of 0.5
g/dl from baseline within 48 h, was significantly lower in
he ANP group than in the control group (3.2% vs. 11.7%,
espectively; p  0.015). Multivariate analysis revealed that
he use of 155 ml of contrast medium (odds ratio: 6.89;
 0.001) and ANP treatment (odds ratio: 0.24; p 
.016) were significant predictors of developing CIN. The
ncidence of an increase in creatinine of 25% or of 0.5
g/dl from baseline at 1 month was also significantly lower
n the ANP group than in the control group (p  0.006).
The natriuretic peptides are a group of structurally similar
ut genetically distinct peptides that have diverse actions in
ardiovascular, renal, and endocrine homeostasis. Both
NP and B-type natriuretic peptide (BNP) are of myocar-
ial cell origin, and C-type natriuretic peptide is of endo-
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ANP and Contrast-Induced Nephropathy March 24, 2009:1047–9helial origin; ANP and BNP bind to the natriuretic
eptide-A receptor, which via 3=,5=-cyclic guanosine mono-
hosphate (cGMP) mediates natriuresis, vasodilation, en-
ances glomerular filtration rate (GFR), renin inhibition,
nd anti-ischemic properties (9). Pre-clinical studies have
hown that ANP and BNP, via the natriuretic peptide-A
eceptor, increases GFR and glomerular hydrostatic pres-
ure by dilating afferent arterioles and constricting efferent
rterioles, while blocking tubular reabsorption of sodium
nd disrupting the tubuloglomerular feedback mechanism
10). Furthermore, they have direct action on the renal
esangial cells to increase glomerular ultrafiltration coeffi-
ient, which in turn increases GFR (11). These renal
nhancing properties together with anti-ischemic and anti-
nflammatory properties have resulted in clinical investiga-
ions to determine the therapeutic potential of ANP and
NP for acute renal failure and the prevention of CIN.
espite encouraging experimental data, initial clinical trails
ith ANP in 2 multicenter, prospective randomized trials in
atients with acute tubular necrosis or late oliguric acute
enal failure were disappointing (12,13). In these studies,
NP, at a dose of 200 ng/kg/min for 24 h, had no effect on
he need for dialysis, the rate of dialysis-free survival at 21
ays after treatment, or overall mortality rate. Subsequently,
ward et al. (14) reported in a single-center, randomized,
ouble-blind, placebo-controlled trial that there was a
ignificant reduction of renal impairment, and of the need
or dialysis after cardiopulmonary bypass, with the use of
ong-term infusion (5 days) of recombinant ANP at a dose of
0 ng/kg/min. The 2 main differences that may account for the
iscrepancies of their results and previous studies are the dose
f ANP used and the duration of ANP infusion. The earlier
tudies used a high dose of ANP at 200 ng/kg/min, whereas
ward et al. (14) used the low dose of 50 ng/kg/min, which
as associated with less hypotension as compared with the
arlier high-dose studies. Furthermore, in the earlier stud-
es, the infusion duration was only 24 h, whereas Sward et
l. (14) infused ANP for 5 days. Similarly, Krunik et al. (15)
eported that ANP infusion at 10, 50, and 100 ng/kg/min
nitiated at 30 min before and continued for 30 min after the
ngiographic procedure did not reduce the incidence of
IN in patients with chronic renal insufficiency. Compar-
tively, in the study by Morikawa et al. (8), the investigators
nfused ANP at 42 ng/kg/min initiated at 4 to 6 h before
ngiography and continued for 48 h, and showed that it was
ffective in preventing CIN. More importantly, this strategy
lso prevented worsening renal function at 1 month. This
upports the concept that in addition to the dose, the
uration of infusion is an important determinant in the
fficacy of ANP in preventing CIN. Hence, Morikawa et al.
8) should be commended for making the effort to review
he previous studies and determining the appropriate dose
nd duration of infusion for their study. Despite the
avorable renal enhancing actions of both ANP and BNP,
he hypotension associated with higher doses results in
ecreased renal perfusion pressure, limits the renal enhanc-ng actions, and may even have detrimental renal effects.
his is also shown in the clinical investigations of BNP
nesiritide), in which studies have shown that at the clinical
ose or higher (2-g/kg bolus followed by continuous
nfusion of 0.01 g/kg/min), there is little renal enhancing
ction and it may even be associated with worsening renal
unction (16,17). In contrast, at lower doses (0.01 or 0.005
g/kg/min without bolus), there are renal enhancing or
reserving properties (18–20).
In summary, CIN is a common cause of hospital-
cquired acute renal failure and is associated with increased
orbidity and mortality. There is currently no established
ptimal strategy for the prevention of CIN. The study by
orikawa et al. (8) has shown the potential of administra-
ion of ANP to prevent CIN. More importantly, the
nvestigators have carefully determined the effective dose
nd duration of intervention. A large multiple-center, ran-
omized, placebo-controlled trial that is adequately pow-
red with clinical end points such as reduction in dialysis,
ospital stay, etc., is clearly warranted based on the prom-
sing results from this pilot study.
eprint requests and correspondence: Dr. Horng H. Chen,
ardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic
nd Foundation, 200 First Street SW, Rochester, Minnesota
5905. E-mail: chen.horng@mayo.edu.
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